A study of a new medicine to prevent fever in children on chemotherapy
Treatments studied
Part of Cancer clinical trials.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 18 years old (but not yet 18).
- You have a type of cancer that does not start in the bone marrow or lymph system, such as solid tumors.
- You are getting intensive chemotherapy and need a medicine (G-CSF) to prevent fever caused by low white blood cell counts, either for the first time or because you had fever or low counts in a previous round.
- You are generally able to do daily activities even if you need rest (score 50 or higher on a 0–100 scale).
- Your blood counts (white blood cells, platelets, and hemoglobin) are within healthy ranges, and your liver and kidney function tests are normal or only slightly high.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial tests a new drug, Efbemalenograstim Alfa (a type of G-CSF), to prevent a drop in white blood cells (neutropenia) that can happen after chemotherapy combined with immunotherapy. It is for people with advanced lung or esophageal cancer who are at high risk for this complication.
This study looks at whether changing the timing of pegfilgrastim (a medicine used to help prevent low white blood cell counts during chemotherapy) affects outcomes in people with primary breast cancer. It may help your care team choose the best dosing schedule for you during treatment.
This trial tests a new way to give a medicine that helps your body make white blood cells after chemotherapy for breast cancer. It may help prevent serious infections.
This trial tests a medication called efbemalenograstim alfa to help prevent a serious drop in white blood cells (febrile neutropenia) in people with advanced lung cancer who are starting their first round of chemo. It may reduce the risk of infection and other complications.
Hear when a new Chemotherapy-induced Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.